Conferences

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.

With additional testing for nonobstructive coronary artery disease (CAD), researchers effectively diagnosed microvascular and/or vasospastic angina—as well as non-cardiac related chest pain—and used that information to guide therapy decisions and significantly improve angina and quality-of-life outcomes.

Intravascular ultrasound (IVUS)-guided stent implantation offers improved clinical outcomes for heart patients over a traditional angiography-guided approach, researchers from China reported at this week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, California.

The Eluvia drug-eluting vascular stent system has been approved by the FDA, device maker Boston Scientific announced Sept. 24—just two days after results from the IMPERIAL trial were presented at the Transcatheter Cardiovascular Therapeutics 2018 meeting.

A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego.

SAN DIEGO — An endovascular ultrasound-based renal denervation (RDN) approach led to greater reductions in blood pressure than radiofrequency ablation in patients with resistant hypertension, according to the first randomized trial to compare the techniques.

OAC-ALONE, the first randomized trial to test the efficacy of oral anticoagulation (OAC) alone against combined OAC and a single antiplatelet agent (APT) in patients with atrial fibrillation and stable coronary artery disease, was unable to establish noninferiority of OACs to dual therapy, according to data presented at the 30th annual TCT conference in San Diego.

SAN DIEGO — General and local anesthesia are comparably safe and effective during transcatheter aortic valve replacement (TAVR) procedures, according to the first randomized trial to compare the two approaches.

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

SAN DIEGO — The ultra-thin Orsiro drug-eluting stent (DES) maintained superior outcomes at two years of follow-up in a head-to-head trial against Abbott’s Xience stent, according to results presented this weekend at Transcatheter Cardiovascular Therapeutics 2018 and published online in the Journal of the American College of Cardiology.

Gregg W. Stone, MD, had the unenviable task of condensing the 255-page agenda for next weekend’s Transcatheter Cardiovascular Therapeutics (TCT) meeting into a handful of highlights during a 12-minute media briefing on Thursday, Sept. 13.